Artiva Biotherapeutics, Inc. - 8-K Filing
Artiva Biotherapeutics entered into an underwriting agreement on May 8, 2026, with Jefferies LLC, TD Securities (USA) LLC, and Cantor Fitzgerald & Co. to issue and sell 23,871,526 shares of common stock at $11.52 per share and pre-funded warrants for 2,170,138 shares at $11.5199 each, raising approximately $300 million in gross proceeds before underwriting discounts and expenses. The offering is expected to close on May 11, 2026. (Items: 8.01 Other Events, 9.01 Financial Statements and Exhibits)
Tickers: $ARTV